Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavarin

Description

The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of the treatment with sofosbuvir velpatasvir (SOF/VEL) fixed-dose combination (FDC) with ribavirin (RBV) for 12 weeks in participants with chronic hepatitis C virus (HCV) infection and Child-Pugh-Turcotte (CPT) class C cirrhosis.

Study Start Date

January, 23 2017

Estimated Completion Date

May 2018

Interventions

  • Drug: RBV
  • Drug: SOF/VEL

Study ID

Gilead Sciences -- GS-US-342-4022

Status

Recruiting

Trial ID

NCT02994056

Study Type

Interventional

Trial Phase

Phase 2

Enrollment Quota

50

Sponsor

Gilead Sciences

Key

Inclusion Criteria

  • A body mass index (BMI) of ? 18 kg/m^2
  • Chronic HCV infection (? 6 months) as documented by either prior medical history or liver biopsy
  • Quantifiable HCV RNA at screening
  • Individuals may be non-transplanted or with recurrent HCV post-liver transplant.
  • If listed for liver transplant, then the projected date of transplant must be ?12 weeks after Day1 of treatment
  • If post-liver transplant, then Day1 must be ? 6 months from date of transplant
  • CPT score of 10 to 12, inclusive, as determined at screening
  • Liver imaging within 6 months of Day 1 to exclude hepatocellular carcinoma (HCC)
  • If treatment-experienced, the most recent HCV treatment must have been completed at least 8 weeks prior to Screening
  • Females of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test on Day 1 prior to randomization
  • Males and females of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception
  • Females must agree to refrain from egg donation and in vitro fertilization during treatment until at least 30 days after the last dose of SOF/VEL or 6 months after the last dose of RBV, whichever occurs last
  • Lactating females must agree to discontinue nursing before the study drugs are administered
  • Males must agree to refrain from sperm donation from the date of screening until at least 7 months after the last dose of RBV or 30 days after the last dose of SOF/VEL, whichever occurs last
  • Adults must be able to comply with the dosing instructions for study drug administration and able to complete the study schedule of assessments Key

Exclusion Criteria

  • Current or prior history of any of the following:
  • Clinically significant medical or psychiatric illness or individual is currently under evaluation for a potentially clinically significant illness
  • Gastrointestinal disorder or post-operative condition that could interfere with the absorption of the study drug
  • Difficulty with blood collection and/or poor venous access for the purposes of phlebotomy
  • Significant pulmonary disease, significant cardiac disease or porphyria
  • Malignancy within the 5 years prior to screening, with the exception of specific cancers that have been cured by surgical resection (basal cell skin cancer, etc.). Adults under evaluation for possible malignancy are not eligible
  • Significant drug allergy (such as anaphylaxis or hepatotoxicity)
  • Any history of organ transplant other than liver or kidney
  • Chronic liver disease of a non-HCV etiology
  • Inability to exclude HCC by imaging within 6 months of Day 1
  • Alpha-fetoprotein (AFP) > 50 unless negative imaging for hepatic masses within the last 6 months or during screening
  • Active spontaneous bacterial peritonitis at screening
  • Infection requiring systemic antibiotics at the time of screening
  • Evidence of fibrosing cholestatic hepatitis at screening
  • Life threatening serious adverse event (SAE) during screening
  • Active variceal bleeding within 6 months of screening
  • Prior placement of a portosystemic shunt (such as TIPS)
  • ECG with clinically significant abnormalities
  • Laboratory parameters with clinically significant abnormalities
  • Hepatitis B surface antigen positive at screening
  • Infection with human immunodeficiency virus (HIV)
  • Clinically-relevant alcohol or drug abuse within 12 months of screening. A positive drug screen will exclude individuals unless it can be explained by a prescribed medication
  • the diagnosis and prescription must be approved by the Investigator
  • Prior exposure to any HCV Non-structural Protein 5A (NS5A) inhibitor
  • Current use of corticosteroids at any dose >10 mg of prednisone/day (or equivalent dose of corticosteroid)
  • Use of any prohibited concomitant medications
  • Use of granulocyte macrophage colony-stimulating factor (GM-CSF), epoetin alfa or other hematopoietic stimulating agents within 2 weeks of screening
  • Male with pregnant female partner
  • History of clinically significant hemoglobinopathy (eg, sickle cell disease, thalassemia)
  • Contraindications to RBV therapy
  • Known hypersensitivity to VEL, RBV, SOF, the metabolites, or formulation excipients
  • Participation in a clinical study with an investigational drug or biologic within 3 months prior to Day 1 NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.

Gender

All

Ages

18 Years and older

Accepts Healthy Volunteers

No

Study Locations and Contact Information (65)

Study Location Distance Name Phone Email
Beth Israel Deaconess Medical - Boston, Massachusetts 2.4 miles None None None
Icahn School of Medicine at Mount Sinai - New York, New York 183.2 miles None None None
Icahn School of Medicine at Mount Sinai - New York, New York 183.2 miles None None None
Icahn School of Medicine at Mount Sinai - New York, New York 183.2 miles None None None
Icahn School of Medicine at Mount Sinai - New York, New York 183.2 miles None None None
Icahn School of Medicine at Mount Sinai - New York, New York 183.2 miles None None None
Weill Cornell Medical Center - New York, New York 184.8 miles None None None
Weill Cornell Medical Center - New York, New York 184.8 miles None None None
Weill Cornell Medical Center - New York, New York 184.8 miles None None None
Weill Cornell Medical Center - New York, New York 184.8 miles None None None
Weill Cornell Medical Center - New York, New York 184.8 miles None None None
University of Pennsylvania - Philadelphia, Pennsylvania 270.8 miles None None None
University of Pennsylvania - Philadelphia, Pennsylvania 270.8 miles None None None
University of Pennsylvania - Philadelphia, Pennsylvania 270.8 miles None None None
University of Pennsylvania - Philadelphia, Pennsylvania 270.8 miles None None None
University of Pennsylvania - Philadelphia, Pennsylvania 270.8 miles None None None
John Hopkins University - Baltimore, Maryland 356.0 miles None None None
Digestive Disease Associates PA - Catonsville, Maryland 362.6 miles None None None
Digestive Disease Associates PA - Catonsville, Maryland 362.6 miles None None None
Digestive Disease Associates PA - Catonsville, Maryland 362.6 miles None None None
Digestive Disease Associates PA - Catonsville, Maryland 362.6 miles None None None
Digestive Disease Associates PA - Catonsville, Maryland 362.6 miles None None None
Liver Institute of VirginiaMcManus - Newport News, Virginia 463.4 miles None None None
Liver Institute of VirginiaMcManus - Newport News, Virginia 463.4 miles None None None
Liver Institute of VirginiaMcManus - Newport News, Virginia 463.4 miles None None None
Liver Institute of VirginiaMcManus - Newport News, Virginia 463.4 miles None None None
Liver Institute of VirginiaMcManus - Newport News, Virginia 463.4 miles None None None
Bon Secours St Marys Hospital of Richmond - Richmond, Virginia 475.0 miles None None None
Bon Secours St Marys Hospital of Richmond - Richmond, Virginia 475.0 miles None None None
Bon Secours St Marys Hospital of Richmond - Richmond, Virginia 475.0 miles None None None
Bon Secours St Marys Hospital of Richmond - Richmond, Virginia 475.0 miles None None None
Bon Secours St Marys Hospital of Richmond - Richmond, Virginia 475.0 miles None None None
Duke University Medical Center - Durham, North Carolina 606.5 miles None None None
Duke University Medical Center - Durham, North Carolina 606.5 miles None None None
Duke University Medical Center - Durham, North Carolina 606.5 miles None None None
Duke University Medical Center - Durham, North Carolina 606.5 miles None None None
Duke University Medical Center - Durham, North Carolina 606.5 miles None None None
Northwestern University - Chicago, Illinois 847.9 miles None None None
Washington University School of Medicine - Saint Louis, Missouri 1,039.5 miles None None None
Washington University School of Medicine - Saint Louis, Missouri 1,039.5 miles None None None
Tampa General Medical Group - Tampa, Florida 1,186.3 miles None None None
Southern Therapy and Advanced Research LLC - Ridgeland, Mississippi 1,248.7 miles None None None
Southern Therapy and Advanced Research LLC - Ridgeland, Mississippi 1,248.7 miles None None None
Methodist Healthcare Dallas The Liver institute - Dallas, Texas 1,552.6 miles None None None
Methodist Healthcare Dallas The Liver institute - Dallas, Texas 1,552.6 miles None None None
Methodist Healthcare Dallas The Liver institute - Dallas, Texas 1,552.6 miles None None None
Methodist Healthcare Dallas The Liver institute - Dallas, Texas 1,552.6 miles None None None
Methodist Healthcare Dallas The Liver institute - Dallas, Texas 1,552.6 miles None None None
University of Colorado School of Medicine - Aurora, Colorado 1,759.8 miles None None None
University of Colorado Denver and Hospital - Aurora, Colorado 1,759.8 miles None None None
American Research Corporation at Texas Liver Institute - San Antonio, Texas 1,766.6 miles None None None
American Research Corporation at Texas Liver Institute - San Antonio, Texas 1,766.6 miles None None None
American Research Corporation at Texas Liver Institute - San Antonio, Texas 1,766.6 miles None None None
American Research Corporation at Texas Liver Institute - San Antonio, Texas 1,766.6 miles None None None
American Research Corporation at Texas Liver Institute - San Antonio, Texas 1,766.6 miles None None None
Intermountain Medical Center - Murray, Utah 2,098.3 miles None None None
Intermountain Medical Center - Murray, Utah 2,098.3 miles None None None
Intermountain Medical Center - Murray, Utah 2,098.3 miles None None None
Intermountain Medical Center - Murray, Utah 2,098.3 miles None None None
Intermountain Medical Center - Murray, Utah 2,098.3 miles None None None
University of Washington - Seattle, Washington 2,487.2 miles None None None
University of Washington - Seattle, Washington 2,487.2 miles None None None
University of Washington - Seattle, Washington 2,487.2 miles None None None
University of Washington - Seattle, Washington 2,487.2 miles None None None
University of Washington - Seattle, Washington 2,487.2 miles None None None

ClinicalTrialsLocator.com provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from ClinicalTrials.gov. This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.